MY170725A - Dengue-virus serotype neutralizing antibodies - Google Patents

Dengue-virus serotype neutralizing antibodies

Info

Publication number
MY170725A
MY170725A MYPI2014700529A MYPI2014700529A MY170725A MY 170725 A MY170725 A MY 170725A MY PI2014700529 A MYPI2014700529 A MY PI2014700529A MY PI2014700529 A MYPI2014700529 A MY PI2014700529A MY 170725 A MY170725 A MY 170725A
Authority
MY
Malaysia
Prior art keywords
dengue
neutralizing antibodies
virus serotype
virus
serotype neutralizing
Prior art date
Application number
MYPI2014700529A
Inventor
Chayanee Setthapramote
Tadahiro Sasaki
Motoki Kuhara
Pongrama Ramasoota
Aree Thattiyaphong
Surapee Anantapreecha
Pathom Sawanpanyalert
Yoshinobu Okuno
Kazuyoshi Ikuta
Atchareeya A-Nuegoonpipat
Panadda Dhepakson
Apichai Prachasuphap
Pattarin Prawatsilpa
Original Assignee
Univ Osaka
Univ Osaka Res Found For Microbial Diseases
Medical & Biol Lab Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Osaka, Univ Osaka Res Found For Microbial Diseases, Medical & Biol Lab Co Ltd filed Critical Univ Osaka
Publication of MY170725A publication Critical patent/MY170725A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Materials and methods are provided for treating dengue infections. Human monoclonal antibodies against all serotypes of dengue virus are also provided. Methods of using human monoclonal antibodies to neutralize all dengue?virus serotypes are provided using patients' peripheral blood lymphocytes. Fig. 1
MYPI2014700529A 2011-09-09 2012-09-07 Dengue-virus serotype neutralizing antibodies MY170725A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161532671P 2011-09-09 2011-09-09
US201161532605P 2011-09-09 2011-09-09

Publications (1)

Publication Number Publication Date
MY170725A true MY170725A (en) 2019-08-27

Family

ID=47116163

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014700529A MY170725A (en) 2011-09-09 2012-09-07 Dengue-virus serotype neutralizing antibodies

Country Status (5)

Country Link
AU (1) AU2012305807B2 (en)
MY (1) MY170725A (en)
PH (1) PH12014500544B1 (en)
SG (1) SG11201400100SA (en)
WO (1) WO2013035345A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2938590C (en) * 2014-02-11 2023-10-17 Visterra, Inc. Antibody molecules to dengue virus and uses thereof
CN105137068B (en) * 2015-07-24 2017-03-01 鲁东大学 Florfenicol Site Detection reagent paper and its preparation, using method
CN105004860B (en) * 2015-07-24 2016-09-21 鲁东大学 Florfenicol rapid detection kit and its preparation and use method
JP7155009B2 (en) 2016-03-25 2022-10-18 ビステラ， インコーポレイテッド Preparation of antibody molecules against dengue virus
CN109929033B (en) * 2019-03-15 2020-06-02 中国人民解放军军事科学院军事医学研究院 A human antibody that specifically binds four serotypes of dengue virus

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5169939A (en) 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
GB8800077D0 (en) 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
DE69233528T2 (en) 1991-11-25 2006-03-16 Enzon, Inc. Process for the preparation of multivalent antigen-binding proteins
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
DE69303494T2 (en) 1992-11-13 1997-01-16 Idec Pharma Corp THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES AGAINST HUMAN B LYMPHOCYTIC LIMITED DIFFERENTIATION ANTIQUES FOR THE TREATMENT OF B CELL LYMPHOMA
DE4337197C1 (en) 1993-10-30 1994-08-25 Biotest Pharma Gmbh Process for the selective preparation of hybridoma cell lines which produce monoclonal antibodies with high cytotoxicity against human CD16 antigen, and the preparation of bispecific monoclonal antibodies using such monoclonal antibodies and the CD30-HRS-3 antibody for therapy of human tumours
EP0985033A4 (en) 1997-04-04 2005-07-13 Biosite Inc Polyvalent and polyclonal libraries
AU2004215125B2 (en) * 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
WO2007119808A1 (en) * 2006-04-13 2007-10-25 Medical And Biological Laboratories Co., Ltd. Fusion partner cells
WO2009011941A2 (en) * 2007-04-04 2009-01-22 The Government Of U.S.A., As Represented By The Secretary, Departmetnt Of Health & Human Services Monoclonal antibodies against dengue and other viruses with deletion in fc region
CN102272155B (en) * 2008-10-13 2018-05-25 生物医学研究所 Dengue virus neutralizing antibody and use thereof
US8975378B2 (en) * 2008-12-25 2015-03-10 Osaka University Human anti-human influenza virus antibody
SG173482A1 (en) * 2009-02-10 2011-09-29 Univ Nanyang Tech Antibodies for diagnosis and treatment of flaviviral infections

Also Published As

Publication number Publication date
PH12014500544A1 (en) 2014-04-21
SG11201400100SA (en) 2014-06-27
WO2013035345A2 (en) 2013-03-14
AU2012305807A8 (en) 2014-03-13
WO2013035345A3 (en) 2013-09-06
AU2012305807B2 (en) 2015-08-20
PH12014500544B1 (en) 2019-03-13
AU2012305807A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
CY1123739T1 (en) ANTI-CD38 ANTIBODIES
PH12017501075A1 (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
EA201300016A1 (en) HUMAN ANTIBODY CONJUGATES AGAINST TISSUE FACTOR WITH DRUGS
EA201490004A1 (en) BIFIDOBACTERIUM LACTIS BL-04 APPLICATION FOR TREATMENT OF RESPIRATORY DISEASES
PH12016500859B1 (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
UA112288C2 (en) Antibody forvulation and therapeutic regimens
PH12015501558A1 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
UA109633C2 (en) HUMAN ANTIBODY AGAINST TISSUE FACTOR
IN2014DN07149A (en)
UA109658C2 (en) ANTIBODY AGAINST CGRP
MX350200B (en) Human antibodies and antibody-drug conjugates against cd74.
EA201690310A1 (en) HUMAN CD27 ANTIBODIES AND THEIR APPLICATION
DE602007013618D1 (en) ANTIBODIES TO THE HUMAN CYTOMEGALIE VIRUS (HCMV)
EA201590562A1 (en) БЕНЗАМИДЫ
BR112013032456A2 (en) anti-cxcr4 antibody with effector functions and its use for cancer treatment
EA201300132A1 (en) PHARMACEUTICAL COMPOSITION AND METHODS OF TREATMENT AND PREVENTION OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV
MX2020001493A (en) TREATMENT WITH OBINUTUZUMAB NEW SUBGROUP OF PATIENTS WITH NEW DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL).
PH12014500544B1 (en) Dengue-virus serotype neutralizing antibodies
MX356745B (en) A human monoclonal antibody against the vp1 protein of jc virus.
UA109148C2 (en) ANTIBODY COMPOSITES AGAINST VEGFR-3
EA201390417A1 (en) ANTI-DIABETIC SOLID PHARMACEUTICAL COMPOSITIONS
MX2013010367A (en) COMPOSITIONS AND METHODS FOR INFLUENZA THERAPY AND DIAGNOSIS.
WO2012119989A3 (en) Antibodies against cadmi for the diagnosis and treatment of cancer
MX2013009529A (en) Treatment of fistulizing crohn's disease.
WO2012149525A3 (en) Ureaplasma vaccine and antibody for prevention and treatment of human, animal and cell culture infection